NanoVibronix Inc. (NAOV)
7.16
-0.18 (-2.45%)
At close: Apr 17, 2025, 3:59 PM
-2.45% (1D)
| Bid | 7.12 |
| Market Cap | 5.44M |
| Revenue (ttm) | 2.56M |
| Net Income (ttm) | -3.71M |
| EPS (ttm) | -151.03 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | -0.05 |
| Analyst | n/a |
| Ask | 7.22 |
| Volume | 96,381 |
| Avg. Volume (20D) | 2,519,209 |
| Open | 7.30 |
| Previous Close | 7.34 |
| Day's Range | 7.05 - 7.55 |
| 52-Week Range | 1.92 - 16.25 |
| Beta | 1.84 |
About NAOV
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter...
Industry Medical - Devices
Sector Healthcare
IPO Date May 28, 2015
Employees 31
Stock Exchange NASDAQ
Ticker Symbol NAOV
Website https://www.nanovibronix.com
1 week ago
+4.96%
NanoVibronix shares are trading higher after the c...
Unlock content with
Pro Subscription
1 month ago
+55.2%
NanoVibronix shares are trading higher on possible continued strength after the company announced on Friday that it published its UroShield study, which showed positive data, including an 86% UTI reduction.
2 months ago · businesswire.com
NanoVibronix, Inc. Announces Acquisition of ENvue Medical Holdings, Corp.ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced the completion of the...